Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT04052373
Recruiting Not applicable

Peri-implantitis Implantoplasty Treatment

NCT04052373 · tracked via the Priya Life Science Norway tracker
Phase
Not applicable
Started
2019-10-15
Last updated
2026-04-29

Condition(s) studied

Peri-ImplantitisPeri-implant Mucositis

Investigational drug(s) / intervention(s)

ImplantoplastyOpen flap debridement alone

Implantoplasty: Implantoplasty is the mechanical smoothening of rough titanium implants as part of the surgical treatment of peri-implantitis. Treatment is thought to facilitate self-performed oral hygiene.

Open flap debridement alone: Open flap debridement alone

Study summary

This double arm, split-mouth, single centre, controlled, randomised clinical study is designed to examine the effect of implantoplasty in treatment of peri-implantitis.

Peri-implantitis will be treated with open flap debridement, with or without implantoplasty.

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Peri-implantitis (according to 2018 criteria) on minimum 2 implants of similar surface and defect type * Competent to give consent * Exposed, modified implant surface with loss \>2mm Exclusion Criteria: * Previous radiotherapy to the jaws, current use of chemotherapy, systemic long-term corticosteroid treatment * Present or past use of bisphosphonate treatment • Pregnant or nursing subjects * Patients classified as \> class II according to ASA classification * Implant unavailable for implantoplasty treatment * Inhability to comprehend and respond to the quality of life questionnaire * Examiners/operators deem original placement of implant (angle, position) suboptimal and considered to play a major role in development of peri-implantitis * History of peri-implantitis surgery prior to 6 months of screening

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Institute of Clinical Dentistry, Faculty of Dentistry, University of Oslo Oslo Oslo Recruiting
Institute of Clinical Dentistry, University of Oslo, Norway Oslo Norway Recruiting

More University of Oslo trials in Norway

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04052373 on ClinicalTrials.gov ↗ ← All trials in Norway